{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:44:17Z","timestamp":1793043857738,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T00:00:00Z","timestamp":1287014400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/leu.2010.234","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T10:21:48Z","timestamp":1287051708000},"page":"82-88","source":"Crossref","is-referenced-by-count":151,"title":["Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients"],"prefix":"10.1038","volume":"25","author":[{"given":"D","family":"Caramazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K H","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,14]]},"reference":[{"key":"BFleu2010234_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358\u2013367.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2010234_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/sj.leu.2404948","volume":"22","author":"A Pardanani","year":"2008","unstructured":"Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23\u201330.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/sj.leu.2405080","volume":"22","author":"N Kroger","year":"2008","unstructured":"Kroger N, Mesa RA . Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474\u2013486.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/leu.2008.56","volume":"22","author":"TL Lasho","year":"2008","unstructured":"Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A . TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008; 22: 1790\u20131792.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2009.50","volume":"23","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A . CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441\u20131445.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/bmt.2009.193","volume":"45","author":"A Tefferi","year":"2010","unstructured":"Tefferi A . Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 2010; 45: 419\u2013421.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2010234_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G . Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia 2008; 22: 905\u2013914.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR8","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895\u20132901.","journal-title":"Blood"},{"key":"BFleu2010234_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u20131708.","journal-title":"Blood"},{"key":"BFleu2010234_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1600-0609.2009.01298.x","volume":"83","author":"T Hidaka","year":"2009","unstructured":"Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol 2009; 83: 328\u2013333.","journal-title":"Eur J Haematol"},{"key":"BFleu2010234_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A . International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115: 496\u2013499.","journal-title":"Blood"},{"key":"BFleu2010234_CR12","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113: 4171\u20134178.","journal-title":"Blood"},{"key":"BFleu2010234_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","volume":"113","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW . Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763\u2013771.","journal-title":"Br J Haematol"},{"key":"BFleu2010234_CR14","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1182\/blood-2004-11-4319","volume":"105","author":"K Strasser-Weippl","year":"2005","unstructured":"Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4146.","journal-title":"Blood"},{"key":"BFleu2010234_CR15","first-page":"17","volume-title":"World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues","author":"JW Vardiman","year":"2001","unstructured":"Vardiman JW, Brunning RD, Harris NL . WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press: Lyon, France, 2001, pp 17\u201344."},{"key":"BFleu2010234_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-4608(85)90032-9","volume":"18","author":"GW Dewald","year":"1985","unstructured":"Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV . The efficacy of direct, 24-h culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985; 18: 1\u201310.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFleu2010234_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756\u2013761.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR18","volume-title":"ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"LG Shaffer","year":"2009","unstructured":"Shaffer LG, Slovak ML, Campbell LJ (eds). ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Karger: Basel, 2009."},{"key":"BFleu2010234_CR19","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1182\/blood-2009-12-258988","volume":"115","author":"E Rumi","year":"2010","unstructured":"Rumi E, Passamonti F, Bernasconi P, Arcaini L, Pietra D, Elena C et al. Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood 2010; 115: 2719\u20132720.","journal-title":"Blood"},{"key":"BFleu2010234_CR20","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/cncr.22630","volume":"109","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109: 2083\u20132088.","journal-title":"Cancer"},{"key":"BFleu2010234_CR21","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; 112: 2726\u20132732.","journal-title":"Cancer"},{"key":"BFleu2010234_CR22","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol 2009; 27: 5587\u20135593.","journal-title":"J Clin Oncol"},{"key":"BFleu2010234_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905\u2013911.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/leu.2009.225","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105\u2013109.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/leu.2010.113","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302\u20131309.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A . Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299\u20131307.","journal-title":"Leukemia"},{"key":"BFleu2010234_CR27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477\u20131483.","journal-title":"Blood"},{"key":"BFleu2010234_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2141.2007.06776.x","volume":"139","author":"R Gupta","year":"2007","unstructured":"Gupta R, Soupir CP, Johari V, Hasserjian RP . Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139: 265\u2013268.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2010234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2010234","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2010234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:03:18Z","timestamp":1684432998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BFleu2010234"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.234","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,14]]}}}